Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

Exclusion Criteria

• •Has other skin disease or condition that can interfere with HS assessment.
• •Has a positive test for TB, HIV, hepatitis B and/or hepatitis C at Screening.
• •Has a history of retinopathy or known clinically significant cardiovascular or hematologic conditions.
• •Has taken any biologic drug within 3 serum half-lives. A list of potential biologics and their half-lives
• •Has started oral antibiotics within 28 days of Study Day 1.
• •Has, within 2 weeks prior to Day 1, received a medication prohibited based on cytochrome P450 (CYP3A4) interaction
• •Has such extensive disease that, in the opinion of the Investigator, it is difficult to discriminate between active lesions and scarring.
• •Has more than 15 active tunnels at Screening.
• •Is pregnant, nursing or considering becoming pregnant.
• •Has a history of malignancy except non-melanoma skin cancer or cervical carcinoma in situ.